Aminoterminal Propeptide of Type III Procollagen and Matrix Metalloproteinases-2 and -9 Failed to Serve as Serum Markers for Abdominal Aortic Aneurysm

Eugster, Thomas; Huber, Andreas; Obeid, Tammam; Schwegler, Igor; Gürke, Lorenz; Stierli, P.

doi:10.1016/j.ejvs.2004.12.007

Cited by 40 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sangiorgi et al reported higher serum levels of matrix metalloproteinase (MMP)-9 in patients with aortic aneurysm; however, a much larger study by Eugster and colleagues did not confirm these findings. 43,44 Although these aortic biopsy and blood assessments give clues as to the mechanisms taking place in end-stage AAA they cannot clarify the initiating pathways since many of the abnormalities demonstrated will be a consequence of the underlying pathological processes.…”

Section: Studies On Human Tissue and Serummentioning

confidence: 99%

Abdominal Aortic Aneurysm

Golledge

Muller

Daugherty

et al. 2006

ATVB

530

231

View full text Add to dashboard Cite

Abstract-Abdominal aortic aneurysm (AAA) affects approximately 5% of elderly men and is responsible for a significant number of deaths in Western Countries. At present surgery by open or endovascular means is the only widely used therapy for this condition. In this review we examine the risk factors, serum, and genetic associations of AAA. Epidemiology studies suggest that smoking cessation and control of cholesterol and blood pressure should reduce the number of patients developing AAA. Natural history studies suggest that smoking cessation should reduce the rate of progression of AAA. Clear level 1 evidence for drug treatments of AAA are presently lacking; however, animal and human in vitro studies suggest that medication targeted at reducing inflammation and proteolysis are most likely to be beneficial, with limited data to support the use of statins, Angiotensin II inhibitors, and macrolides. Work has commenced in understanding which patients, identified by clinical, serum, and genotype, are more at risk of AAA progression and thus should be selected out for aggressive treatment.Well designed large multicenter randomized controlled trials are required to examine the medical treatment of AAA.

show abstract

Section: Studies On Human Tissue and Serummentioning

confidence: 99%

Abdominal Aortic Aneurysm

Golledge

Muller

Daugherty

et al. 2006

ATVB

530

231

View full text Add to dashboard Cite

show abstract

“…These include degradation products of elastin (18,19) and collagen (28), proteases (20,21), and inflammation markers such as cytokines (15,31) and c-reactive protein (27). However, a clear biomarker has yet to emerge, as these markers are not AAA specific, and many of the studies have conflicting results (8,23). Hence, there is urgent, unmet need for a sensitive and specific biomarker for AAA.…”

mentioning

confidence: 99%

Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm

Siu

Cai

2014

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Siu KL, Cai H. Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm. Am J Physiol Heart Circ Physiol 307: H1559 -H1564, 2014. First published September 26, 2014 doi:10.1152/ajpheart.00444.2014.-Rupture of abdominal aortic aneurysm (AAA) is unpredictable and lethal. A clinically valid biomarker to monitor the disease has not been available. Based on our recent discoveries that uncoupled endothelial nitric oxide synthase (eNOS)/tetrahydrobiopterin deficiency plays a causal role in various models of AAA, the present study examined the relationship between circulating and tissue levels of tetrahydrobiopterin (H4B) in angiotensin II-infused hyperphenylalaninemia (hph-1) and apoE null mice. For apoE null mice, tissue and plasma H4B levels decreased time dependently, to 2.69 Ϯ 0.15 and 1.99 Ϯ 0.06 pmol/mg, respectively (from 4.86 Ϯ 0.32 and 3.31 Ϯ 0.13 pmol/mg at baseline) by week 3, when aneurysms developed. For hph-1 mice, tissue and plasma H4B levels decreased significantly to 1.02 Ϯ 0.10 and 0.98 Ϯ 0.09 pmol/mg, respectively (from 1.84 Ϯ 0.18 and 1.48 Ϯ 0.12 pmol/mg at baseline), by week 1, when aneurysms developed. Oral folic acid administration, which has been shown to improve aortic H4B levels to completely prevent or markedly decrease the incidence of AAA, significantly increased tissue and plasma H 4B levels in both animal models starting at week 1. The two H4B measurements at all conditions showed significant linear correlation, suggesting that plasma H 4B accurately predicts its tissue levels when H4B is either reduced or enhanced.Together, these data demonstrate that H4B levels decrease with AAA development and increase with folic acid treatment in two different murine models of AAA and that plasma H 4B levels accurately reflect H4B levels in the tissue, suggesting that circulating H4B levels may be used clinically as a novel and powerful biomarker for the development and response to treatment of AAA.abdominal aortic aneurysm; biomarker; eNOS; folic acid; tetrahydrobiopterin

show abstract

“…23,24 However, these studies revealed contradictory conclusions. The present study showed that aging increases plasma active-MMP-9 level, but decreases the plasma pro-MMP-2 and NGAL-MMP-9 levels (Fig 8B).…”

Section: Discussionmentioning

confidence: 84%

RECS1 is a Negative Regulator of Matrix Metalloproteinase-9 Production and Aged RECS1 Knockout Mice are Prone to Aortic Dilation

Zhao

Ito

Sakai

et al. 2006

Circ J

View full text Add to dashboard Cite

Aminoterminal Propeptide of Type III Procollagen and Matrix Metalloproteinases-2 and -9 Failed to Serve as Serum Markers for Abdominal Aortic Aneurysm

Abstract: Both MMP-2 and -9 and NIIINP failed to show relevance as serum markers for aortic dilatation. Our results are, therefore, in contradiction to previous published results. AAAs cannot be diagnosed with a simple blood test.

Cited by 40 publications

References 33 publications

Abdominal Aortic Aneurysm

Abdominal Aortic Aneurysm

Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm

RECS1 is a Negative Regulator of Matrix Metalloproteinase-9 Production and Aged RECS1 Knockout Mice are Prone to Aortic Dilation

Contact Info

Product

Resources

About